Walking Fish to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company
RNS Number : 4333Y MaxCyte, Inc. 04 May 2023 MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell platform Walking Fish to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based
RNS Number : 3213Y MaxCyte, Inc. 03 May 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options, PDMR dealing and Total Voting Rights Gaithersburg, Maryland - 3 May 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing
RNS Number : 0314W MaxCyte, Inc. 13 April 2023 MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023 ROCKVILLE, MD , April 13, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support
RNS Number : 8160U MaxCyte, Inc. 30 March 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") PDMR Dealing Gaithersburg, Maryland - 30 March 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 3628U MaxCyte, Inc. 28 March 2023 MaxCyte Appoints Douglas Swirsky as Chief Financial Officer Rockville, MD , March 28, 2023 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
ROCKVILLE, Md., March 27, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support
RNS Number : 7652T MaxCyte, Inc. 22 March 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options and PDMR Dealing Gaithersburg, Maryland - 22 March 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 1392T MaxCyte, Inc. 16 March 2023 MaxCyte announces filing of Form 10-K for the full year period ended December 31, 2022 ROCKVILLE, MD , March 16, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
